Cancer News and Research

Latest Cancer News and Research

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

11 Feb 2010

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

11 Feb 2010

41st Annual Meeting on Women's Cancer to be hosted in San Francisco, California

The Society of Gynecologic Oncologists (SGO) will host its 41st Annual Meeting on Women's Cancer March 14-17, 2010 at the Moscone West Convention Center in San Francisco, California. This year's meeting will feature more than 434 scientific presentations in addition to lectures, workshops, symposia and postgraduate courses that focus on emerging science, clinical trials and treatment advances for physicians and health care professionals in the field of gynecologic oncology.

11 Feb 2010

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

11 Feb 2010

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Elbit Imaging Ltd. announces that its associated company (approximately 28% holding on a fully diluted basis), Gamida Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV), announced today that the Data Monitoring Committee ("DMC") has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

11 Feb 2010

Lawmakers in Kansas, Idaho prepare measures to pre-empt any national mandate to purchase insurance

"Kansas lawmakers have heard testimony on a proposed amendment to the state Constitution asserting Kansans' right to refuse to buy health insurance. Proponents of the measure call it a response to Democratic proposals in Congress that they say would force people to buy health insurance or face penalties for failing to do so." Supporters of the amendment believe the mandate in the national legislation is unconstitutional (2/9).

11 Feb 2010

LUHS nurses earn professional certifications

Several Loyola University Health System (LUHS) nurses have earned professional certifications in their clinical areas of expertise. This indicates that LUHS nurses meet strong professional development standards and competencies.

11 Feb 2010

FDA to take closer look at medical radiation, devices

The Food and Drug Administration will step up oversight of three forms of medical radiation, including CT scans, in an effort to reduce patients' exposure to unnecessary radiation, The New York Times reports.

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Celebrity promotes fundraising event fro cancer research

KIMBERLY WYATT from the "Pussycat Dolls" has shone brightly to promote Cancer Research UK's latest fundraising event by posing in a bespoke, illuminated dress designed especially for her

11 Feb 2010

BioSphere Medical reports fourth-quarter and full-year 2009 results

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported financial results for the three and 12 months ended December 31, 2009.

10 Feb 2010

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

University of Adelaide researchers in Australia are finding new ways to block the movement of cells in the body which can cause autoimmune diseases and the spread of cancer.

10 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

EMEA grants Genta's request for SME designation

Genta Incorporated announced that it has received $2.8 million in non-dilutive cash proceeds from the sale of net operating tax losses and research tax credits generated in prior tax years as part of the Technology Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority (NJEDA), pursuant to the rules, regulations and stipulations set forth by the program.

10 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Cancer News and Research

Latest Cancer News and Research

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

41st Annual Meeting on Women's Cancer to be hosted in San Francisco, California

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Lawmakers in Kansas, Idaho prepare measures to pre-empt any national mandate to purchase insurance

LUHS nurses earn professional certifications

FDA to take closer look at medical radiation, devices

CINJ researchers develop new vaccine strategy for pancreatic cancer

Celebrity promotes fundraising event fro cancer research

BioSphere Medical reports fourth-quarter and full-year 2009 results

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

Trimel BioPharma Holdings updates business developments

EMEA grants Genta's request for SME designation

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Medicinal chemistry paper related to the discovery of CUDC-101 published

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

YM BioSciences receives additional AeroLEF patents in U.S.

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in